Bioequivalence studies in India | Spinos Life Science

India has emerged as a leading destination for conducting bioequivalence studies due to its well-developed infrastructure, skilled workforce, and cost-effective services. In fact, the country conducts around 50% of all bioequivalence studies globally. One of the major reasons for the popularity of bioequivalence studies in India is the cost advantage. The cost of conducting these studies in India is significantly lower compared to developed countries like the US and Europe. This makes it a lucrative option for pharmaceutical companies seeking to have their generic drugs approved for market entry. India's growing emphasis on research and development in the pharmaceutical sector has also contributed to the popularity of bioequivalence studies in the country. The government's initiatives to promote and support research have attracted both domestic and international pharmaceutical companies to conduct their studies in India. At SpinoS Life Science, we specialise in comprehensive BE services—including study design, site management, bioanalysis, and regulatory documentation—to help sponsors and manufacturers seamlessly navigate India’s regulatory framework and deliver high-quality, globally acceptable data.